New book by Larry Connors Click here Improve your trading - See how
The funds will be used for the development of the company's vaccines for infectious diseases that include influenza, human papillomavirus (HPV), respiratory syncytial virus (RSV) and dengue. Specifically, the Company plans to fund several clinical trials, including a Phase II clinical trial of its M2e universal flu vaccine and a Phase I clinical trial of its seasonal flu vaccine in an elderly population.
VaxInnate is already working on a prototype swine flu vaccine that could be available for preclinical animal studies in as early as six weeks. If successful, VaxInnate's swine flu vaccine could be manufactured in a matter of weeks and at volumes sufficient to rapidly meet global vaccination needs.
"We're delighted to add The Wellcome Trust to our roster of shareholders and gratified to see our investors' continuing interest in VaxInnate," said CEO Alan Shaw, PhD. "The additional funding will make it possible for us to continue advancing our flu vaccines forward to market and to support the application of our technology platform to vaccines for other infectious diseases, among them HPV, RSV and the emerging swine flu."
The Wellcome Trust is the world's largest medical research charity and the largest charity in the United Kingdom. The Wellcome Trust funds innovative biomedical research in the UK and internationally to produce knowledge that can be used to protect and improve human and animal health, investing more than GBP 600 million annually to support the brightest scientists with the best ideas.
"Wellcome is very pleased to support the development of VaxInnate's proprietary technology and innovative vaccines, having recognized both the scientific validation and the commercial value of its approach," said Julie Eskay-Eagle of The Wellcome Trust.
Eskay-Eagle, who heads the healthcare team for The Wellcome Trust's investment division, joined the VaxInnate Board of Directors.
"We believe VaxInnate's paradigm-shifting vaccine technology platform is positioned to address key challenges in the marketplace at a time when industry, government and the public sector are working together to improve our ability to meet global health needs," said Board member Seth Berkley, MD, president and founder of the International AIDS Vaccine Initiative (IAVI) and a specialist in infectious disease, epidemiology and international health. "We welcome Julie Eskay-Eagle to the VaxInnate Board and look forward to benefiting from her experience and counsel."
About VaxInnate
VaxInnate is a privately-held biotechnology company in Cranbury, NJ that is pioneering breakthrough technology for use in developing novel and proprietary vaccines. VaxInnate's technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of vaccines.
VaxInnate's first vaccines focus on infectious diseases, including seasonal and pandemic flu, malaria, dengue, human papillomavirus and respiratory syncytial virus. In 2008 and 2009, VaxInnate generated positive Phase I clinical data for its first two vaccines, a universal flu vaccine and a seasonal flu vaccine. For more information about VaxInnate, please visit http://www.vaxinnate.com.
SOURCE: VaxInnate Corporation
VaxInnate Corporation Contact: Janet Skidmore, 215-658-4915 Mobile: 215-429-2917 skidmorecomm@earthlink.net
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
